The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study
Abstract
Objective: We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized anti–interleukin‐17 (anti–IL‐17) monoclonal antibody, in a first in‐human trial in rheumatoid arthritis (RA) patients taking oral disease‐modifying antirheumatic drugs (DMARDs). Methods: This randomized, double‐blind, placebo‐controlled study consisted of 2 parts. In part A, 20 patients received 1 intravenous (IV) dose of LY2439821 (0.06, 0.2, 0.6, or 2.0 mg/kg, escalating) or placebo followed by 8 weeks of evaluation. End points included safety, tolerability, and pharmacokinetics. In part B, 77 patients received 1 IV dose of LY2439821 (0.2, 0.6, or 2.0 mg/kg) or placebo every 2 weeks for a total of 5 doses, with a total evaluation period of 16 weeks. End points included safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy (Disease Activity Score in 28 joints [DAS28] and percentages of patients meeting American College of Rheumatology 20%, 50%, or 70% improvement criteria [achieving an ACR20, ACR50, or ACR70 response]). The primary efficacy end point was the DAS28 at week 10. Results: Baseline characteristics were similar across all groups. Changes in the DAS28 were significantly greater in the 0.2 mg/kg, 2.0 mg/kg, and all‐LY2439821–combined groups (−2.3, −2.4, and −2.3, respectively) than in the placebo group (−1.7) at week 10 ( P ≤ 0.05), and these differences were significant as early as week 1. Percentages of ACR20, ACR50, and ACR70 responses as well as improvements in the ACR core set of measures were greater in LY2439821‐treated patients than in placebo‐treated patients at multiple time points. There was no apparent dose‐response relationship in treatment‐emergent adverse events. Conclusion: LY2439821 added to oral DMARDs improved signs and symptoms of RA, with no strong adverse safety signal noted. This first evaluation of LY2439821 supports neutralization of IL‐17 as a potential novel goal for the treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.519 · Cited by 1,521
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice
Nakae, S., Nambu, A., Sudo, K., & Iwakura, Y. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6173 · Cited by 1,273
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Cited by
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
Noack, M., & Miossec, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.12.004 · Cited by 932
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Osteoimmunology: evolving concepts in bone–immune interactions in health and disease
Tsukasaki, M., & Takayanagi, H. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0178-8 · Cited by 771
Maddur, M. S., Miossec, P., Kaveri, S. V., & Bayry, J. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.044 · Cited by 619
Sano, T., Huang, W., Hall, J. A., Yang, Y., Chen, A., Gavzy, S. J., Lee, J.-Y., Ziel, J. W., Miraldi, E. R., Domingos, A. I., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.061 · Cited by 547
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
IL-17 cytokines in immunity and inflammation
Jin, W., & Dong, C. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.58 · Cited by 529
Innate lymphoid cells in the initiation, regulation and resolution of inflammation
Sonnenberg, G. F., & Artis, D. (2015) · Nature Medicine · doi:10.1038/nm.3892 · Cited by 503
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke
Gelderblom, M., Weymar, A., Bernreuther, C., Velden, J., Arunachalam, P., Steinbach, K., Orthey, E., Arumugam, T. V., Leypoldt, F., Simova, O., et al. (2012) · Blood · doi:10.1182/blood-2012-02-412726 · Cited by 457
Role of Th17 cells in human autoimmune arthritis
Leipe, J., Grunke, M., Dechant, C., Reindl, C., Kerzendorf, U., Schulze‐Koops, H., & Skapenko, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27622 · Cited by 448
The IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405
Obesity, Fat Mass and Immune System: Role for Leptin
Francisco, V., Pino, J., Campos-Cabaleiro, V., Ruiz-Fernández, C., Mera, A., Gonzalez-Gay, M. A., Gómez, R., & Gualillo, O. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00640 · Cited by 411
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Zhu, S., Pan, W., Song, X., Liu, Y., Shao, X., Tang, Y., Liang, D., He, D., Wang, H., Liu, W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2815 · Cited by 396
CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity
Wang, C., Yosef, N., Gaublomme, J., Wu, C., Lee, Y., Clish, C. B., Kaminski, J., Xiao, S., Zu Horste, G. M., Pawlak, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.068 · Cited by 392
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Griffin, G. K., Newton, G., Tarrio, M. L., Bu, D.-X., Maganto-Garcia, E., Azcutia, V., Alcaide, P., Grabie, N., Luscinskas, F. W., Croce, K. J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200385 · Cited by 364
Interleukin-17 and innate immunity in infections and chronic inflammation
Isailovic, N., Daigo, K., Mantovani, A., & Selmi, C. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.006 · Cited by 363
Th17 cells in immunity to Candida albicans
Hernández-Santos, N., & Gaffen, S. L. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.04.008 · Cited by 361
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637829 · Cited by 360
Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Rincon, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328
Crosstalk Between Gut Microbiota and Innate Immunity and Its Implication in Autoimmune Diseases
Jiao, Y., Wu, L., Huntington, N. D., & Zhang, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00282 · Cited by 321
Effect of IL-17A blockade with secukinumab in autoimmune diseases
Patel, D. D., Lee, D. M., Kolbinger, F., & Antoni, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202371 · Cited by 313
Emerging cell and cytokine targets in rheumatoid arthritis
Burmester, G. R., Feist, E., & Dörner, T. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.168 · Cited by 307
Colony stimulating factors and myeloid cell biology in health and disease
Hamilton, J. A., & Achuthan, A. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.08.006 · Cited by 285
Recent advances in the IL-17 cytokine family
Gaffen, S. L. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.07.006 · Cited by 283
IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential
Zhu, S., & Qian, Y. (2012) · Clinical Science · doi:10.1042/cs20110496 · Cited by 282
Pappu, R., Ramirez-Carrozzi, V., & Sambandam, A. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03465.x · Cited by 281
Etiology and Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2017) · Kelley and Firestein's Textbook of Rheumatology · doi:10.1016/b978-0-323-31696-5.00069-3 · Cited by 278
Xiao, S., Yosef, N., Yang, J., Wang, Y., Zhou, L., Zhu, C., Wu, C., Baloglu, E., Schmidt, D., Ramesh, R., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.004 · Cited by 276
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211
IL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling
Garg, A. V., Ahmed, M., Vallejo, A. N., Ma, A., & Gaffen, S. L. (2013) · Science Signaling · doi:10.1126/scisignal.2003699 · Cited by 128
Pineda, M. A., Lumb, F., Harnett, M. M., & Harnett, W. (2014) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2014.03.003 · Cited by 88
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Sardar, S., & Andersson, Å. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1125917 · Cited by 50
The origin and role of innate lymphoid cells in the lung
Lai, D.-M., Shu, Q., & Fan, J. (2016) · Military Medical Research · doi:10.1186/s40779-016-0093-2 · Cited by 45
Interleukin-17A antagonist attenuates radiation-induced lung injuries in mice
Wang, B.-Z., Wang, L.-P., Han, H., Cao, F.-L., Li, G.-Y., Xu, J.-L., Wang, X.-W., & Wang, L.-X. (2014) · Experimental Lung Research · doi:10.3109/01902148.2013.872210 · Cited by 33
Life before seventeen: cloning of the IL-17 receptor
Gaffen, S. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102576 · Cited by 22
“Conversely, Th17 cells and IL-17 itself promote pathology in autoimmune disease models, inspiring clinical trials of anti–IL-17A Abs as therapies for various autoimmune disorders (48, 49).”
Background
Metadata
- Authors
- Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P., & Sloan‐Lancaster, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-03-30
- Volume
- 62
- Issue
- 4
- Pages
- 929-939
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2076456688
- Cited by
- 451
- References
- 23
- FWCI
- 44.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.